http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2465103-C
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2f73a8d824f0bb76033ff0d97e34355d http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_44c713790ce00813da2e6c6d57a29456 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5575 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C405-00 |
| filingDate | 2003-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19bd3c55f641aab9709f3412a51495df http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3f3b54c3a8bba64e4c538754aa0e891 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64518515c187145c0ea80feeb1d33410 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e07240f4559038bab3d9f1a2f346ecc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08ad4df7dbb281ce557bd68244639090 |
| publicationDate | 2011-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2465103-C |
| titleOfInvention | Use of a prostaglandin derivative as an anti-pruritic agent |
| abstract | A pharmaceutical preparation for preventing or treating pruritic symptoms which contains as an effective ingredient a prostaglandin derivative represented by formula [1] (see formula 1) wherein X1 and X2 which are different from each other represent a hydrogen atom, a halogen atom or a hydroxyl group; Y is an ethylene group, a vinylene group or an ethynylene group; Z is the formula (CH2)k A(CH2)h B(CH2)q, (CH2)k A(CH2)r A'(CH2)t, (CH2)k B(CH2)h B'(CH2)q or (CH2)k-1B'(CH2)q-1A' wherein k is an integer of 1 to 4, h is an integer of 0 to 4, q is an integer 1 to 4, r is an integer of 0 to 4, and t is an integer of 0 to 2; A and A' which may be the same or different represent an ethylene group, a vinylene group or an ethynylene group; B and B' which may be the same or different represent an oxygen atom or a group represented by the formula S(O), wherein u is an integer of 0 to 2; W1 is a hydroxyl group, a C1-10 alkyloxy group, a C3-10 cycloalkyloxy group, an aryloxy group or an arylalkyloxy group; W2 is a C1-10 alkyl group, a C2-10 alkenyl group, a C2-10 alkynyl group, a C3-10 cycloalkyl group, a C1-5 alkyl group substituted by C3-10 cycloalkyl group(s), or a group represented by the formula (see above formula) wherein W4 is a C1-10 alkyl group, a C2-10 alkenyl group, a C2-10 alkynyl group or a C1-5 alkyl group substituted by C3-10 cycloalkyl group(s); v is an integer of 0 to 4; W3 is a hydrogen atom or a methyl group, or W3 when taken together with W2 and the adjacent carbon atom forms a C3-10 cycloalkyl group; m is 0 or 1, a pharmaceutically acceptable salt thereof or a hydrate thereof. |
| priorityDate | 2002-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 147.